Kiniksa Pharmaceuticals International (KNSA) Competitors $54.09 -0.19 (-0.34%) As of 03:53 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KNSA vs. GMAB, ASND, SMMT, BBIO, and RGCShould you buy Kiniksa Pharmaceuticals International stock or one of its competitors? MarketBeat compares Kiniksa Pharmaceuticals International with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kiniksa Pharmaceuticals International include Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), Summit Therapeutics (SMMT), BridgeBio Pharma (BBIO), and Regencell Bioscience (RGC). These companies are all part of the "pharmaceutical products" industry. KNSA vs. GMABKNSA vs. ASNDKNSA vs. SMMTKNSA vs. BBIOKNSA vs. RGCHow does Kiniksa Pharmaceuticals International compare to Genmab A/S?Genmab A/S (NASDAQ:GMAB) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment. Do analysts rate GMAB or KNSA? Genmab A/S presently has a consensus price target of $39.07, indicating a potential upside of 44.27%. Kiniksa Pharmaceuticals International has a consensus price target of $60.86, indicating a potential upside of 12.02%. Given Genmab A/S's stronger consensus rating and higher probable upside, analysts plainly believe Genmab A/S is more favorable than Kiniksa Pharmaceuticals International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genmab A/S 1 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.83Kiniksa Pharmaceuticals International 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 Does the media refer more to GMAB or KNSA? In the previous week, Kiniksa Pharmaceuticals International had 2 more articles in the media than Genmab A/S. MarketBeat recorded 3 mentions for Kiniksa Pharmaceuticals International and 1 mentions for Genmab A/S. Kiniksa Pharmaceuticals International's average media sentiment score of 1.19 beat Genmab A/S's score of 0.30 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kiniksa Pharmaceuticals International 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in GMAB or KNSA? 7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by company insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is GMAB or KNSA more profitable? Genmab A/S has a net margin of 21.05% compared to Kiniksa Pharmaceuticals International's net margin of 9.69%. Genmab A/S's return on equity of 15.34% beat Kiniksa Pharmaceuticals International's return on equity.Company Net Margins Return on Equity Return on Assets Genmab A/S21.05% 15.34% 8.94% Kiniksa Pharmaceuticals International 9.69%13.26%9.86% Which has more volatility & risk, GMAB or KNSA? Genmab A/S has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.17, suggesting that its stock price is 83% less volatile than the broader market. Which has better earnings and valuation, GMAB or KNSA? Genmab A/S has higher revenue and earnings than Kiniksa Pharmaceuticals International. Genmab A/S is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenmab A/S$3.90B4.33$963M$1.3220.52Kiniksa Pharmaceuticals International$677.56M6.17$59.01M$0.9060.37 SummaryGenmab A/S beats Kiniksa Pharmaceuticals International on 9 of the 16 factors compared between the two stocks.How does Kiniksa Pharmaceuticals International compare to Ascendis Pharma A/S?Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings. Is KNSA or ASND more profitable? Ascendis Pharma A/S has a net margin of 57.87% compared to Kiniksa Pharmaceuticals International's net margin of 9.69%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Ascendis Pharma A/S's return on equity.Company Net Margins Return on Equity Return on Assets Kiniksa Pharmaceuticals International9.69% 13.26% 9.86% Ascendis Pharma A/S 57.87%N/A -8.37% Which has more volatility and risk, KNSA or ASND? Kiniksa Pharmaceuticals International has a beta of 0.17, indicating that its share price is 83% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market. Does the media prefer KNSA or ASND? In the previous week, Ascendis Pharma A/S had 2 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 5 mentions for Ascendis Pharma A/S and 3 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.19 beat Ascendis Pharma A/S's score of 0.67 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kiniksa Pharmaceuticals International 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, KNSA or ASND? Kiniksa Pharmaceuticals International has higher earnings, but lower revenue than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiniksa Pharmaceuticals International$677.56M6.17$59.01M$0.9060.37Ascendis Pharma A/S$814.57M18.88-$258M$8.6728.43 Do analysts prefer KNSA or ASND? Kiniksa Pharmaceuticals International presently has a consensus target price of $60.86, indicating a potential upside of 12.02%. Ascendis Pharma A/S has a consensus target price of $295.39, indicating a potential upside of 19.84%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, analysts clearly believe Ascendis Pharma A/S is more favorable than Kiniksa Pharmaceuticals International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiniksa Pharmaceuticals International 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78Ascendis Pharma A/S 1 Sell rating(s) 0 Hold rating(s) 16 Buy rating(s) 2 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in KNSA or ASND? 54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are held by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryAscendis Pharma A/S beats Kiniksa Pharmaceuticals International on 10 of the 17 factors compared between the two stocks.How does Kiniksa Pharmaceuticals International compare to Summit Therapeutics?Summit Therapeutics (NASDAQ:SMMT) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends. Do institutionals & insiders have more ownership in SMMT or KNSA? 4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media favor SMMT or KNSA? In the previous week, Summit Therapeutics and Summit Therapeutics both had 3 articles in the media. Kiniksa Pharmaceuticals International's average media sentiment score of 1.19 beat Summit Therapeutics' score of 0.32 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Kiniksa Pharmaceuticals International 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate SMMT or KNSA? Summit Therapeutics presently has a consensus target price of $27.58, suggesting a potential upside of 56.77%. Kiniksa Pharmaceuticals International has a consensus target price of $60.86, suggesting a potential upside of 12.02%. Given Summit Therapeutics' higher possible upside, equities research analysts plainly believe Summit Therapeutics is more favorable than Kiniksa Pharmaceuticals International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Summit Therapeutics 2 Sell rating(s) 5 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.50Kiniksa Pharmaceuticals International 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 Which has more volatility and risk, SMMT or KNSA? Summit Therapeutics has a beta of -1.25, indicating that its share price is 225% less volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.17, indicating that its share price is 83% less volatile than the broader market. Is SMMT or KNSA more profitable? Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Summit Therapeutics' net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Summit TherapeuticsN/A -291.24% -243.07% Kiniksa Pharmaceuticals International 9.69%13.26%9.86% Which has stronger earnings & valuation, SMMT or KNSA? Kiniksa Pharmaceuticals International has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSummit TherapeuticsN/AN/A-$1.08B-$1.60N/AKiniksa Pharmaceuticals International$677.56M6.17$59.01M$0.9060.37 SummaryKiniksa Pharmaceuticals International beats Summit Therapeutics on 11 of the 15 factors compared between the two stocks.How does Kiniksa Pharmaceuticals International compare to BridgeBio Pharma?BridgeBio Pharma (NASDAQ:BBIO) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations. Is BBIO or KNSA more profitable? Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to BridgeBio Pharma's net margin of -124.42%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat BridgeBio Pharma's return on equity.Company Net Margins Return on Equity Return on Assets BridgeBio Pharma-124.42% N/A -65.81% Kiniksa Pharmaceuticals International 9.69%13.26%9.86% Which has more volatility & risk, BBIO or KNSA? BridgeBio Pharma has a beta of 1.02, indicating that its stock price is 2% more volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.17, indicating that its stock price is 83% less volatile than the broader market. Do analysts recommend BBIO or KNSA? BridgeBio Pharma currently has a consensus price target of $88.90, suggesting a potential upside of 25.67%. Kiniksa Pharmaceuticals International has a consensus price target of $60.86, suggesting a potential upside of 12.02%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe BridgeBio Pharma is more favorable than Kiniksa Pharmaceuticals International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BridgeBio Pharma 1 Sell rating(s) 1 Hold rating(s) 23 Buy rating(s) 0 Strong Buy rating(s) 2.88Kiniksa Pharmaceuticals International 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 Which has better valuation & earnings, BBIO or KNSA? Kiniksa Pharmaceuticals International has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBridgeBio Pharma$502.08M27.60-$724.93M-$3.74N/AKiniksa Pharmaceuticals International$677.56M6.17$59.01M$0.9060.37 Does the media refer more to BBIO or KNSA? In the previous week, BridgeBio Pharma had 9 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 12 mentions for BridgeBio Pharma and 3 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.19 beat BridgeBio Pharma's score of 0.29 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kiniksa Pharmaceuticals International 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders have more ownership in BBIO or KNSA? 99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryKiniksa Pharmaceuticals International beats BridgeBio Pharma on 9 of the 16 factors compared between the two stocks.How does Kiniksa Pharmaceuticals International compare to Regencell Bioscience?Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Regencell Bioscience (NASDAQ:RGC) are both pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends. Do analysts recommend KNSA or RGC? Kiniksa Pharmaceuticals International currently has a consensus price target of $60.86, indicating a potential upside of 12.02%. Given Kiniksa Pharmaceuticals International's stronger consensus rating and higher probable upside, equities analysts plainly believe Kiniksa Pharmaceuticals International is more favorable than Regencell Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiniksa Pharmaceuticals International 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has more risk and volatility, KNSA or RGC? Kiniksa Pharmaceuticals International has a beta of 0.17, meaning that its share price is 83% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.88, meaning that its share price is 88% more volatile than the broader market. Is KNSA or RGC more profitable? Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Regencell Bioscience's net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Regencell Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Kiniksa Pharmaceuticals International9.69% 13.26% 9.86% Regencell Bioscience N/A N/A N/A Which has stronger earnings and valuation, KNSA or RGC? Kiniksa Pharmaceuticals International has higher revenue and earnings than Regencell Bioscience. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiniksa Pharmaceuticals International$677.56M6.17$59.01M$0.9060.37Regencell BioscienceN/AN/A-$3.58MN/AN/A Do institutionals & insiders believe in KNSA or RGC? 54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are held by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are held by company insiders. Comparatively, 2.0% of Regencell Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media prefer KNSA or RGC? In the previous week, Regencell Bioscience had 14 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 17 mentions for Regencell Bioscience and 3 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.19 beat Regencell Bioscience's score of 0.00 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kiniksa Pharmaceuticals International 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 16 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryKiniksa Pharmaceuticals International beats Regencell Bioscience on 11 of the 13 factors compared between the two stocks. Get Kiniksa Pharmaceuticals International News Delivered to You Automatically Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KNSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KNSA vs. The Competition ExportMetricKiniksa Pharmaceuticals InternationalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.18B$3.35B$6.33B$12.27BDividend YieldN/A2.32%2.80%5.36%P/E Ratio60.3719.0220.9125.45Price / Sales6.17278.31520.5273.05Price / Cash67.20125.3543.1855.00Price / Book6.906.8910.007.01Net Income$59.01M$24.23M$3.54B$335.03M7 Day Performance-7.19%0.74%0.38%-0.43%1 Month Performance27.98%-0.46%-0.04%0.99%1 Year Performance108.00%63.21%34.86%34.43% Kiniksa Pharmaceuticals International Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KNSAKiniksa Pharmaceuticals International3.921 of 5 stars$54.09-0.3%$60.86+12.5%+103.3%$4.16B$677.56M60.08220Positive NewsAnalyst UpgradeGMABGenmab A/S4.1345 of 5 stars$26.90+1.3%$39.07+45.2%+33.8%$16.77B$3.72B20.383,029Gap DownASNDAscendis Pharma A/S3.7641 of 5 stars$245.49+0.8%$291.50+18.7%+49.4%$15.31B$865.78M28.311,189Analyst UpgradeSMMTSummit Therapeutics2.7724 of 5 stars$18.14-3.5%$27.58+52.1%-26.7%$14.08BN/AN/A110Analyst DowngradeOptions VolumeBBIOBridgeBio Pharma3.4244 of 5 stars$69.66+1.5%$88.19+26.6%+102.4%$13.64B$579.96MN/A400Analyst ForecastInsider Trade Related Companies and Tools Related Companies Genmab A/S Alternatives Ascendis Pharma A/S Alternatives Summit Therapeutics Alternatives BridgeBio Pharma Alternatives Regencell Bioscience Alternatives Axsome Therapeutics Alternatives Dr. Reddy's Laboratories Alternatives Arrowhead Pharmaceuticals Alternatives Elanco Animal Health Alternatives Cytokinetics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KNSA) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals International, plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiniksa Pharmaceuticals International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
